Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

MedWellAI (MWAI) EBITDA (2016 - 2025)

MedWellAI (MWAI) has disclosed EBITDA for 11 consecutive years, with -$265417.0 as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 12.88% to -$265417.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$454040.0, a 111.51% decrease, with the full-year FY2025 number at -$761736.0, up 68.06% from a year prior.
  • EBITDA was -$265417.0 for Q4 2025 at MedWellAI, up from -$317727.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $11.9 million in Q2 2021 to a low of -$22.2 million in Q2 2023.
  • A 5-year average of -$1.8 million and a median of -$333772.0 in 2021 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 2046.24% in 2021; the steepest drop was 4747.28% in 2021.
  • MedWellAI's EBITDA stood at -$331865.0 in 2021, then crashed by 84.01% to -$610649.0 in 2022, then soared by 45.03% to -$335679.0 in 2023, then increased by 9.24% to -$304648.0 in 2024, then rose by 12.88% to -$265417.0 in 2025.
  • Per Business Quant, the three most recent readings for MWAI's EBITDA are -$265417.0 (Q4 2025), -$317727.0 (Q3 2025), and $1.9 million (Q2 2025).